Q&A: Janssen on where it is heading with real world evidence
Executive Summary
Getting to grips with real world evidence can help companies get their medicines to patients, but there are multiple challenges too, such as “messy” data and building trust, says Nigel Hughes of Janssen Pharmaceutical.
You may also be interested in...
Real World Evidence Is Critical To Pharma’s Future: Can We Agree On What It Is?
Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.
Real-World Evidence And The Quest For European Market Access
Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.